Vesicular Stomatitis Virus-Based Vaccine Protects Mice against Crimean-Congo Hemorrhagic Fever

Crimean-Congo hemorrhagic fever virus (CCHFV), a tick-borne bunyavirus, can cause a life-threatening hemorrhagic syndrome in humans but not in its animal host. The virus is widely distributed throughout southeastern Europe, the Middle East, Africa, and Asia. Disease management has proven difficult a...

Celý popis

Uložené v:
Podrobná bibliografia
Vydané v:Scientific reports Ročník 9; číslo 1; s. 7755 - 13
Hlavní autori: Rodriguez, Sergio E., Cross, Robert W., Fenton, Karla A., Bente, Dennis A., Mire, Chad E., Geisbert, Thomas W.
Médium: Journal Article
Jazyk:English
Vydavateľské údaje: London Nature Publishing Group UK 23.05.2019
Nature Publishing Group
Nature Portfolio
Predmet:
ISSN:2045-2322, 2045-2322
On-line prístup:Získať plný text
Tagy: Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
Abstract Crimean-Congo hemorrhagic fever virus (CCHFV), a tick-borne bunyavirus, can cause a life-threatening hemorrhagic syndrome in humans but not in its animal host. The virus is widely distributed throughout southeastern Europe, the Middle East, Africa, and Asia. Disease management has proven difficult and there are no broadly licensed vaccines or therapeutics. Recombinant vesicular stomatitis viruses (rVSV) expressing foreign glycoproteins (GP) have shown promise as experimental vaccines for several viral hemorrhagic fevers. Here, we developed and assessed a replication competent rVSV vector expressing the CCHFV glycoprotein precursor (GPC), which encodes CCHFV structural glycoproteins. This construct drives strong expression of CCHFV-GP, in vitro . Using these vectors, we vaccinated STAT-1 knock-out mice, an animal model for CCHFV. The vector was tolerated and 100% efficacious against challenge from a clinical strain of CCHFV. Anti-CCHFV-GP IgG and neutralizing antibody titers were observed in surviving animals. This study demonstrates that a rVSV expressing only the CCHFV-GP has the potential to serve as a replication competent vaccine platform against CCHF infections.
AbstractList Crimean-Congo hemorrhagic fever virus (CCHFV), a tick-borne bunyavirus, can cause a life-threatening hemorrhagic syndrome in humans but not in its animal host. The virus is widely distributed throughout southeastern Europe, the Middle East, Africa, and Asia. Disease management has proven difficult and there are no broadly licensed vaccines or therapeutics. Recombinant vesicular stomatitis viruses (rVSV) expressing foreign glycoproteins (GP) have shown promise as experimental vaccines for several viral hemorrhagic fevers. Here, we developed and assessed a replication competent rVSV vector expressing the CCHFV glycoprotein precursor (GPC), which encodes CCHFV structural glycoproteins. This construct drives strong expression of CCHFV-GP, in vitro. Using these vectors, we vaccinated STAT-1 knock-out mice, an animal model for CCHFV. The vector was tolerated and 100% efficacious against challenge from a clinical strain of CCHFV. Anti-CCHFV-GP IgG and neutralizing antibody titers were observed in surviving animals. This study demonstrates that a rVSV expressing only the CCHFV-GP has the potential to serve as a replication competent vaccine platform against CCHF infections.Crimean-Congo hemorrhagic fever virus (CCHFV), a tick-borne bunyavirus, can cause a life-threatening hemorrhagic syndrome in humans but not in its animal host. The virus is widely distributed throughout southeastern Europe, the Middle East, Africa, and Asia. Disease management has proven difficult and there are no broadly licensed vaccines or therapeutics. Recombinant vesicular stomatitis viruses (rVSV) expressing foreign glycoproteins (GP) have shown promise as experimental vaccines for several viral hemorrhagic fevers. Here, we developed and assessed a replication competent rVSV vector expressing the CCHFV glycoprotein precursor (GPC), which encodes CCHFV structural glycoproteins. This construct drives strong expression of CCHFV-GP, in vitro. Using these vectors, we vaccinated STAT-1 knock-out mice, an animal model for CCHFV. The vector was tolerated and 100% efficacious against challenge from a clinical strain of CCHFV. Anti-CCHFV-GP IgG and neutralizing antibody titers were observed in surviving animals. This study demonstrates that a rVSV expressing only the CCHFV-GP has the potential to serve as a replication competent vaccine platform against CCHF infections.
Abstract Crimean-Congo hemorrhagic fever virus (CCHFV), a tick-borne bunyavirus, can cause a life-threatening hemorrhagic syndrome in humans but not in its animal host. The virus is widely distributed throughout southeastern Europe, the Middle East, Africa, and Asia. Disease management has proven difficult and there are no broadly licensed vaccines or therapeutics. Recombinant vesicular stomatitis viruses (rVSV) expressing foreign glycoproteins (GP) have shown promise as experimental vaccines for several viral hemorrhagic fevers. Here, we developed and assessed a replication competent rVSV vector expressing the CCHFV glycoprotein precursor (GPC), which encodes CCHFV structural glycoproteins. This construct drives strong expression of CCHFV-GP, in vitro. Using these vectors, we vaccinated STAT-1 knock-out mice, an animal model for CCHFV. The vector was tolerated and 100% efficacious against challenge from a clinical strain of CCHFV. Anti-CCHFV-GP IgG and neutralizing antibody titers were observed in surviving animals. This study demonstrates that a rVSV expressing only the CCHFV-GP has the potential to serve as a replication competent vaccine platform against CCHF infections.
Crimean-Congo hemorrhagic fever virus (CCHFV), a tick-borne bunyavirus, can cause a life-threatening hemorrhagic syndrome in humans but not in its animal host. The virus is widely distributed throughout southeastern Europe, the Middle East, Africa, and Asia. Disease management has proven difficult and there are no broadly licensed vaccines or therapeutics. Recombinant vesicular stomatitis viruses (rVSV) expressing foreign glycoproteins (GP) have shown promise as experimental vaccines for several viral hemorrhagic fevers. Here, we developed and assessed a replication competent rVSV vector expressing the CCHFV glycoprotein precursor (GPC), which encodes CCHFV structural glycoproteins. This construct drives strong expression of CCHFV-GP, in vitro . Using these vectors, we vaccinated STAT-1 knock-out mice, an animal model for CCHFV. The vector was tolerated and 100% efficacious against challenge from a clinical strain of CCHFV. Anti-CCHFV-GP IgG and neutralizing antibody titers were observed in surviving animals. This study demonstrates that a rVSV expressing only the CCHFV-GP has the potential to serve as a replication competent vaccine platform against CCHF infections.
Crimean-Congo hemorrhagic fever virus (CCHFV), a tick-borne bunyavirus, can cause a life-threatening hemorrhagic syndrome in humans but not in its animal host. The virus is widely distributed throughout southeastern Europe, the Middle East, Africa, and Asia. Disease management has proven difficult and there are no broadly licensed vaccines or therapeutics. Recombinant vesicular stomatitis viruses (rVSV) expressing foreign glycoproteins (GP) have shown promise as experimental vaccines for several viral hemorrhagic fevers. Here, we developed and assessed a replication competent rVSV vector expressing the CCHFV glycoprotein precursor (GPC), which encodes CCHFV structural glycoproteins. This construct drives strong expression of CCHFV-GP, in vitro. Using these vectors, we vaccinated STAT-1 knock-out mice, an animal model for CCHFV. The vector was tolerated and 100% efficacious against challenge from a clinical strain of CCHFV. Anti-CCHFV-GP IgG and neutralizing antibody titers were observed in surviving animals. This study demonstrates that a rVSV expressing only the CCHFV-GP has the potential to serve as a replication competent vaccine platform against CCHF infections.
ArticleNumber 7755
Author Mire, Chad E.
Cross, Robert W.
Rodriguez, Sergio E.
Geisbert, Thomas W.
Fenton, Karla A.
Bente, Dennis A.
Author_xml – sequence: 1
  givenname: Sergio E.
  orcidid: 0000-0003-4149-7458
  surname: Rodriguez
  fullname: Rodriguez, Sergio E.
  organization: Galveston National Laboratory, University of Texas Medical Branch, Department of Microbiology & Immunology, University of Texas Medical Branch
– sequence: 2
  givenname: Robert W.
  surname: Cross
  fullname: Cross, Robert W.
  organization: Galveston National Laboratory, University of Texas Medical Branch, Department of Microbiology & Immunology, University of Texas Medical Branch
– sequence: 3
  givenname: Karla A.
  surname: Fenton
  fullname: Fenton, Karla A.
  organization: Galveston National Laboratory, University of Texas Medical Branch, Department of Microbiology & Immunology, University of Texas Medical Branch
– sequence: 4
  givenname: Dennis A.
  orcidid: 0000-0002-5150-7368
  surname: Bente
  fullname: Bente, Dennis A.
  organization: Galveston National Laboratory, University of Texas Medical Branch, Department of Microbiology & Immunology, University of Texas Medical Branch
– sequence: 5
  givenname: Chad E.
  orcidid: 0000-0001-7596-1808
  surname: Mire
  fullname: Mire, Chad E.
  email: chmire@utmb.edu
  organization: Galveston National Laboratory, University of Texas Medical Branch, Department of Microbiology & Immunology, University of Texas Medical Branch
– sequence: 6
  givenname: Thomas W.
  surname: Geisbert
  fullname: Geisbert, Thomas W.
  email: twgeisbe@utmb.edu
  organization: Galveston National Laboratory, University of Texas Medical Branch, Department of Microbiology & Immunology, University of Texas Medical Branch
BackLink https://www.ncbi.nlm.nih.gov/pubmed/31123310$$D View this record in MEDLINE/PubMed
BookMark eNp9kk1vFSEUhiemxtbaP-DCTOLGzShfA8PGRG-sbVKjiXqXEj7OTLmZCxWYJv57aW-tbRdlA4HnfTlw3ufNXogBmuYlRm8xosO7zHAvhw5h2TFGMOr4k-aAINZ3hBKyd2e93xzlvEF19EQyLJ81-xRjQilGB82vNWRvl1mn9nuJW1188bld-7Tk7qPO4Nq1ttYHaL-lWMCW3H7xFlo9aR9yaVfJb0GHbhXDFNsT2MaUzvXkbXsMl5BeNE9HPWc4upkPm5_Hn36sTrqzr59PVx_OOssRLx3TEoyhwlmhDXIWUccBA7YgeicHQbSRzI5WCCO5GTSYkROGBBdcc2x6etic7nxd1Bt1UYvS6Y-K2qvrjZgmpVPxdgbFyCiIZU4KsEwiPTgpjSMMDGbghrF6vd95XSxmC85CKEnP90zvnwR_rqZ4qXhPKRGyGry5MUjx9wK5qK3PFuZZB4hLVqR2BVPWM1LR1w_QTVxSqF9VKSIJJwPFlXp1t6LbUv61sQJkB9gUc04w3iIYqau4qF1cVI2Luo6L4lU0PBBZX2oA4tWr_Py4lO6kud4TJkj_y35E9RePBNS8
CitedBy_id crossref_primary_10_1038_s41541_021_00293_9
crossref_primary_10_1016_j_antiviral_2019_104573
crossref_primary_10_3389_fcimb_2023_1174030
crossref_primary_10_3390_v14081664
crossref_primary_10_1038_s41541_025_01164_3
crossref_primary_10_1038_s41392_024_01917_x
crossref_primary_10_3390_v16010128
crossref_primary_10_1038_s41598_024_65384_8
crossref_primary_10_1016_j_antiviral_2024_106045
crossref_primary_10_3390_vaccines9121491
crossref_primary_10_1016_j_micpath_2023_106054
crossref_primary_10_1007_s00705_020_04576_9
crossref_primary_10_1016_j_ebiom_2023_104523
crossref_primary_10_1038_s41579_023_00871_9
crossref_primary_10_1128_JVI_02005_19
crossref_primary_10_3390_vaccines13030223
crossref_primary_10_1126_scitranslmed_adq5928
crossref_primary_10_1155_tbed_2303502
crossref_primary_10_1016_j_antiviral_2019_104702
crossref_primary_10_1089_biores_2019_0057
crossref_primary_10_3201_eid3005_231648
crossref_primary_10_3390_vaccines13010073
crossref_primary_10_3390_v17081054
crossref_primary_10_1016_j_ebiom_2022_104188
crossref_primary_10_1080_14712598_2020_1787981
crossref_primary_10_1186_s12575_024_00244_3
crossref_primary_10_1080_14760584_2020_1738225
crossref_primary_10_1097_MRM_0000000000000260
crossref_primary_10_1002_jmv_70457
crossref_primary_10_1016_j_coviro_2020_09_003
crossref_primary_10_3389_fmicb_2022_984536
crossref_primary_10_3390_vaccines7030115
crossref_primary_10_3389_fmicb_2021_817200
crossref_primary_10_1038_s41392_023_01408_5
crossref_primary_10_1016_j_sjbs_2021_12_004
crossref_primary_10_3390_ijms26104893
crossref_primary_10_1038_s41541_024_00877_1
crossref_primary_10_1038_s41541_021_00361_0
crossref_primary_10_3390_v11070590
crossref_primary_10_3390_pathogens10091092
crossref_primary_10_1038_s41467_020_20228_7
crossref_primary_10_1038_s41541_023_00663_5
crossref_primary_10_3389_fcimb_2023_1121163
crossref_primary_10_3389_fimmu_2023_1238882
crossref_primary_10_3389_fcimb_2024_1341332
crossref_primary_10_1186_s12985_023_02089_w
crossref_primary_10_3390_diagnostics13162708
crossref_primary_10_1371_journal_pntd_0008637
crossref_primary_10_1371_journal_pntd_0008834
crossref_primary_10_3389_fcimb_2025_1650652
Cites_doi 10.1371/journal.pntd.0006598
10.1128/JVI.76.14.7263-7275.2002
10.1186/1743-422X-10-353
10.1016/S1473-3099(06)70435-2
10.1016/j.vaccine.2005.08.034
10.1016/j.jviromet.2010.08.006
10.1016/j.virol.2006.11.023
10.1128/JVI.80.1.514-525.2006
10.1093/ofid/ofv082
10.1128/JVI.03691-14
10.1371/journal.pntd.0003579
10.1016/S1473-3099(15)00154-1
10.1073/pnas.92.10.4477
10.1016/j.virol.2008.11.020
10.1016/j.bbrc.2011.06.109
10.1128/JVI.01383-10
10.1371/journal.pone.0091516
10.1099/vir.0.81175-0
10.1371/journal.pone.0094355
10.1128/JVI.00767-07
10.1186/1742-4682-1-10
10.1128/JVI.01647-07
10.1016/j.coviro.2012.03.001
10.1016/j.antiviral.2017.05.010
10.1099/vir.0.80955-0
10.1128/JVI.00661-16
10.1128/JVI.78.10.5458-5465.2004
10.1128/JVI.00794-11
10.1093/infdis/jix189
10.1016/j.antiviral.2017.08.014
10.1371/journal.pntd.0002600
10.1128/JVI.76.16.8011-8018.2002
10.1038/nature14428
10.1371/journal.ppat.1004390
10.1038/s41564-018-0141-7
10.1099/vir.0.019034-0
10.1007/s00705-017-3358-5
10.1128/JVI.02076-16
10.1016/j.antiviral.2013.07.006
10.1093/infdis/jiv188
10.1016/j.vaccine.2017.05.097
10.1016/j.molmed.2004.03.003
10.1016/j.vaccine.2017.05.031
10.1371/journal.ppat.1000225
10.1093/infdis/jix215
10.1128/iai.29.2.744-757.1980
10.1128/JVI.02730-06
10.1017/S0950268814002271
10.1128/jvi.65.9.4950-4958.1991
10.1128/JVI.00573-07
10.1093/infdis/jit061
10.1371/journal.pntd.0005908
10.1016/j.antiviral.2007.11.002
10.1007/s00705-016-2803-1
10.1128/CVI.05352-11
10.1080/21645515.2015.1078045
10.1089/vbz.2015.1855
10.1073/pnas.78.3.1746
10.1016/S0140-6736(16)32621-6
ContentType Journal Article
Copyright The Author(s) 2019
The Author(s) 2019. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Copyright_xml – notice: The Author(s) 2019
– notice: The Author(s) 2019. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
DBID C6C
AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
3V.
7X7
7XB
88A
88E
88I
8FE
8FH
8FI
8FJ
8FK
ABUWG
AEUYN
AFKRA
AZQEC
BBNVY
BENPR
BHPHI
CCPQU
DWQXO
FYUFA
GHDGH
GNUQQ
HCIFZ
K9.
LK8
M0S
M1P
M2P
M7P
PHGZM
PHGZT
PIMPY
PJZUB
PKEHL
PPXIY
PQEST
PQGLB
PQQKQ
PQUKI
Q9U
7X8
5PM
DOA
DOI 10.1038/s41598-019-44210-6
DatabaseName Springer Nature OA Free Journals
CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
ProQuest Central (Corporate)
Health & Medical Collection (Proquest)
ProQuest Central (purchase pre-March 2016)
Biology Database (Alumni Edition)
Medical Database (Alumni Edition)
Science Database (Alumni Edition)
ProQuest SciTech Collection
ProQuest Natural Science Journals
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest One Sustainability
ProQuest Central UK/Ireland
ProQuest Central Essentials - QC
Biological Science Collection
ProQuest Central
Natural Science Collection
ProQuest One
ProQuest Central Korea
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Central Student
SciTech Premium Collection
ProQuest Health & Medical Complete (Alumni)
Biological Sciences
ProQuest Health & Medical Collection
Medical Database
Science Database
Biological Science Database
ProQuest Central Premium
ProQuest One Academic
Publicly Available Content Database
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Applied & Life Sciences
ProQuest One Academic (retired)
ProQuest One Academic UKI Edition
ProQuest Central Basic
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Publicly Available Content Database
ProQuest Central Student
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
SciTech Premium Collection
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Natural Science Collection
ProQuest Biology Journals (Alumni Edition)
ProQuest Central
ProQuest One Applied & Life Sciences
ProQuest One Sustainability
ProQuest Health & Medical Research Collection
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
Natural Science Collection
ProQuest Central Korea
Health & Medical Research Collection
Biological Science Collection
ProQuest Central (New)
ProQuest Medical Library (Alumni)
ProQuest Science Journals (Alumni Edition)
ProQuest Biological Science Collection
ProQuest Central Basic
ProQuest Science Journals
ProQuest One Academic Eastern Edition
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
Biological Science Database
ProQuest SciTech Collection
ProQuest Hospital Collection (Alumni)
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest One Academic UKI Edition
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic

CrossRef
MEDLINE
Publicly Available Content Database


Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: PIMPY
  name: Publicly Available Content Database
  url: http://search.proquest.com/publiccontent
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Biology
EISSN 2045-2322
EndPage 13
ExternalDocumentID oai_doaj_org_article_42f72c4d97ec490a8d99bd24eb14ed8f
PMC6533279
31123310
10_1038_s41598_019_44210_6
Genre Research Support, Non-U.S. Gov't
Journal Article
GrantInformation_xml – fundername: Department of Microbiology and Immunology, UTMB-Galveston
– fundername: ;
GroupedDBID 0R~
3V.
4.4
53G
5VS
7X7
88A
88E
88I
8FE
8FH
8FI
8FJ
AAFWJ
AAJSJ
AAKDD
ABDBF
ABUWG
ACGFS
ACSMW
ACUHS
ADBBV
ADRAZ
AENEX
AEUYN
AFKRA
AJTQC
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AOIJS
AZQEC
BAWUL
BBNVY
BCNDV
BENPR
BHPHI
BPHCQ
BVXVI
C6C
CCPQU
DIK
DWQXO
EBD
EBLON
EBS
EJD
ESX
FYUFA
GNUQQ
GROUPED_DOAJ
GX1
HCIFZ
HH5
HMCUK
HYE
KQ8
LK8
M0L
M1P
M2P
M48
M7P
M~E
NAO
OK1
PIMPY
PQQKQ
PROAC
PSQYO
RNT
RNTTT
RPM
SNYQT
UKHRP
AASML
AAYXX
AFFHD
AFPKN
CITATION
PHGZM
PHGZT
PJZUB
PPXIY
PQGLB
CGR
CUY
CVF
ECM
EIF
NPM
7XB
8FK
K9.
PKEHL
PQEST
PQUKI
Q9U
7X8
5PM
ID FETCH-LOGICAL-c606t-4a9ebb37dc7ab0dc03d6e1e1ce75d9872ab94cfc77b96b8aebf62407676a61b53
IEDL.DBID DOA
ISICitedReferencesCount 55
ISICitedReferencesURI http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000468770600020&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN 2045-2322
IngestDate Fri Oct 03 12:43:56 EDT 2025
Tue Nov 04 01:56:09 EST 2025
Sun Nov 09 13:12:01 EST 2025
Tue Oct 07 07:39:11 EDT 2025
Mon Jul 21 05:40:55 EDT 2025
Sat Nov 29 04:37:49 EST 2025
Tue Nov 18 21:47:46 EST 2025
Fri Feb 21 02:38:51 EST 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Language English
License Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c606t-4a9ebb37dc7ab0dc03d6e1e1ce75d9872ab94cfc77b96b8aebf62407676a61b53
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ORCID 0000-0003-4149-7458
0000-0001-7596-1808
0000-0002-5150-7368
OpenAccessLink https://doaj.org/article/42f72c4d97ec490a8d99bd24eb14ed8f
PMID 31123310
PQID 2229262831
PQPubID 2041939
PageCount 13
ParticipantIDs doaj_primary_oai_doaj_org_article_42f72c4d97ec490a8d99bd24eb14ed8f
pubmedcentral_primary_oai_pubmedcentral_nih_gov_6533279
proquest_miscellaneous_2232134542
proquest_journals_2229262831
pubmed_primary_31123310
crossref_primary_10_1038_s41598_019_44210_6
crossref_citationtrail_10_1038_s41598_019_44210_6
springer_journals_10_1038_s41598_019_44210_6
PublicationCentury 2000
PublicationDate 2019-05-23
PublicationDateYYYYMMDD 2019-05-23
PublicationDate_xml – month: 05
  year: 2019
  text: 2019-05-23
  day: 23
PublicationDecade 2010
PublicationPlace London
PublicationPlace_xml – name: London
– name: England
PublicationTitle Scientific reports
PublicationTitleAbbrev Sci Rep
PublicationTitleAlternate Sci Rep
PublicationYear 2019
Publisher Nature Publishing Group UK
Nature Publishing Group
Nature Portfolio
Publisher_xml – name: Nature Publishing Group UK
– name: Nature Publishing Group
– name: Nature Portfolio
References CollerBGClinical development of a recombinant Ebola vaccine in the midst of an unprecedented epidemicVaccine2017354465446910.1016/j.vaccine.2017.05.097
ZivcecMarkoGuerreroLisa I.W.AlbariñoCésar G.BergeronÉricNicholStuart T.SpiropoulouChristina F.Identification of broadly neutralizing monoclonal antibodies against Crimean-Congo hemorrhagic fever virusAntiviral Research20171461121201:CAS:528:DC%2BC2sXhsVWmt7rK10.1016/j.antiviral.2017.08.014
CanakogluNImmunization of Knock-Out α/β Interferon Receptor Mice against High Lethal Dose of Crimean-Congo Hemorrhagic Fever Virus with a Cell Culture Based VaccinePLoS Negl. Trop. Dis.2015911410.1371/journal.pntd.0003579
HaddockEA cynomolgus macaque model for Crimean–Congo haemorrhagic feverNat. Microbiol.201835565621:CAS:528:DC%2BC1cXnsVGrtro%3D10.1038/s41564-018-0141-7
GeisbertTWVesicular stomatitis virus-based Ebola vaccine is well-tolerated and protects immunocompromised nonhuman primatesPLoS Pathog.20084e100022510.1371/journal.ppat.1000225
AhmedAAPresence of broadly reactive and group-specific neutralizing epitopes on newly described isolates of Crimean-Congo hemorrhagic fever virusJ. Gen. Virol.200586332733361:CAS:528:DC%2BD2MXht12ntL%2FP10.1099/vir.0.81175-0
ErgönülÖCrimean-Congo haemorrhagic feverLancet Infect. Dis.2006620321410.1016/S1473-3099(06)70435-2
GarrisonARA DNA vaccine for Crimean-Congo hemorrhagic fever protects against disease and death in two lethal mouse modelsPLoS Negl. Trop. Dis.201711E000590810.1371/journal.pntd.0005908
MireChad E.GeisbertJoan B.MarziAndreaAgansKrystle N.FeldmannHeinzGeisbertThomas W.Vesicular Stomatitis Virus-Based Vaccines Protect Nonhuman Primates against Bundibugyo ebolavirusPLoS Neglected Tropical Diseases2013712e260010.1371/journal.pntd.0002600
Hinkula, J. et al. Immunization with DNA Plasmids Coding for Crimean-Congo Hemorrhagic Fever Virus Capsid and Envelope Proteins and/or Virus-Like Particles Induces Protection and Survival in Challenged Mice. J. Virol. 91 (2017).
LichtyBDPowerATStojdlDFBellJCVesicular stomatitis virus: Re-inventing the bulletTrends Mol. Med.2004102102161:CAS:528:DC%2BD2cXjs1Wgtbk%3D10.1016/j.molmed.2004.03.003
SimonMJohanssonCLundkvistÅMirazimiAMicrotubule-dependent and microtubule-independent steps in Crimean-Congo hemorrhagic fever virus replication cycleVirology20093853133221:CAS:528:DC%2BD1MXisFOnsbY%3D10.1016/j.virol.2008.11.020
PrebleOTCostelloLEHuangDDBarmadaMANeurovirulence mutant of vesicular stomatitis virus with an altered target cell tropism in vivoInfect. Immun.198029744571:CAS:528:DyaL3cXlt12qurs%3D6163714551188
ErgonulOCrimean-Congo hemorrhagic fever virus: New outbreaks, new discoveriesCurr. Opin. Virol.2012221522010.1016/j.coviro.2012.03.001
Fuchs, J. D. et al. First-in-Human Evaluation of the Safety and Immunogenicity of a Recombinant Vesicular Stomatitis Virus Human Immunodeficiency Virus-1 Vaccine (HVTN 090). Open Forum Infect. Dis. 2 (2015).
SpikKImmunogenicity of combination DNA vaccines for Rift Valley fever virus, tick-borne encephalitis virus, Hantaan virus, and Crimean Congo hemorrhagic fever virusVaccine200624465746661:CAS:528:DC%2BD28XltF2ru7w%3D10.1016/j.vaccine.2005.08.034
Bertolotti-ciarletACellular Localization and Antigenic Characterization of Crimean-Congo Hemorrhagic Fever Virus GlycoproteinsSociety200579615261611:CAS:528:DC%2BD2MXkt1WitLY%3D
MireCEDurability of a vesicular stomatitis virus-based marburg virus vaccine in nonhuman primatesPLoS One201491710.1371/journal.pone.0094355
MireCESingle-dose attenuated Vesiculovax vaccines protect primates against Ebola Makona virusNature20155206886912015Natur.520..688M1:CAS:528:DC%2BC2MXnsVWqtL4%3D10.1038/nature14428
ZivcecMLethal Crimean-Congo hemorrhagic fever virus infection in interferon α/β receptor knockout mice is associated with high viral loads, proinflammatory responses, and coagulopathyJ. Infect. Dis.2013207190919211:CAS:528:DC%2BC3sXotlOgtbY%3D10.1093/infdis/jit061
ButtigiegKRA novel vaccine against Crimean-Congo haemorrhagic fever protects 100% of animals against lethal challenge in a mouse modelPLoS One20149e915162014PLoSO...991516B10.1371/journal.pone.0091516
ShiXKohlALiPElliottRMRole of the cytoplasmic tail domains of Bunyamwera orthobunyavirus glycoproteins Gn and Gc in virus assembly and morphogenesisJ. Virol.20078110151601:CAS:528:DC%2BD2sXhtVehtL%2FP10.1128/JVI.00573-07
GhiasiSMSalmanianAHChinikarSZakeriSMice orally immunized with a transgenic plant expressing the glycoprotein of Crimean-Congo hemorrhagic fever virusClin. Vaccine Immunol.201118203120371:CAS:528:DC%2BC3MXhs1yksrnK10.1128/CVI.05352-11
Shtanko, O., Nikitina, R. A., Altuntas, C. Z., Chepurnov, A. A. & Davey, R. A. Crimean-Congo Hemorrhagic Fever Virus Entry into Host Cells Occurs through the Multivesicular Body and Requires ESCRT Regulators. PLoS Pathog. 10 (2014).
ErgonulOTreatment of Crimean-Congo hemorrhagic feverAntiviral Res.2008781251311:CAS:528:DC%2BD1cXjtleqtLY%3D10.1016/j.antiviral.2007.11.002
BergmannJETokuyasuKTSingerSJPassage of an integral membrane protein, the vesicular stomatitis virus glycoprotein, through the Golgi apparatus en route to the plasma membraneProc. from Natl. Acad. Sci.198178174617501981PNAS...78.1746B1:CAS:528:DyaL3MXhs12ls7k%3D10.1073/pnas.78.3.1746
Henao-RestrepoAMEfficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola Ça Suffi t!)Lancet20173895055181:CAS:528:DC%2BC28XitFGitbbJ10.1016/S0140-6736(16)32621-6
SudaYAnalysis of the entry mechanism of Crimean-Congo hemorrhagic fever virus, using a vesicular stomatitis virus pseudotyping systemArch. Virol.2016161144714541:CAS:528:DC%2BC28XjsFequr4%3D10.1007/s00705-016-2803-1
SanchezAJVincentMJNicholSTCharacterization of the glycoproteins of Crimean-Congo hemorrhagic fever virusJ. Virol.2002767263751:CAS:528:DC%2BD38XltVylsL8%3D10.1128/JVI.76.14.7263-7275.2002
BereczkySCrimean-Congo hemorrhagic fever virus infection is lethal for adult type I interferon receptor-knockout miceJ. Gen. Virol.201091147314771:CAS:528:DC%2BC3cXnsFKhtbo%3D10.1099/vir.0.019034-0
ForgerJMBronsonRTHuangASReissCSMurine infection by vesicular stomatitis virus: initial characterization of the H-2d systemJ. Virol.199165495081:CAS:528:DyaK3MXmtVGku7s%3D1651414248957
DowallSA Crimean-Congo hemorrhagic fever (CCHF) viral vaccine expressing nucleoprotein is immunogenic but fails to confer protection against lethal diseaseHum. Vaccin. Immunother.2016125195271:STN:280:DC%2BC287mt1Gjuw%3D%3D10.1080/21645515.2015.1078045
BenteDACrimean-Congo hemorrhagic fever: History, epidemiology, pathogenesis, clinical syndrome and genetic diversityAntiviral Res.20131001591891:CAS:528:DC%2BC3sXhvVWksLzI10.1016/j.antiviral.2013.07.006
EricksonBRDeydeVSanchezAJVincentMJNicholSTN-linked glycosylation of Gn (but not Gc) is important for Crimean Congo hemorrhagic fever virus glycoprotein localization and transportVirology20073613483551:CAS:528:DC%2BD2sXksV2gtLY%3D10.1016/j.virol.2006.11.023
MireCESingle injection recombinant vesicular stomatitis virus vaccines protect ferrets against lethal Nipah virus diseaseVirol. J.20131035310.1186/1743-422X-10-353
SanchezAJVincentMJEricksonBRNicholSTCrimean-congo hemorrhagic fever virus glycoprotein precursor is cleaved by Furin-like and SKI-1 proteases to generate a novel 38-kilodalton glycoproteinJ. Virol.200680514251:CAS:528:DC%2BD28Xjslalurg%3D10.1128/JVI.80.1.514-525.2006
DevignotSBergeronENicholSMirazimiAWeberFA virus-like particle system identifies the endonuclease domain of Crimean-Congo hemorrhagic fever virusJ. Virol.2015895957671:CAS:528:DC%2BC2MXosFSjtL8%3D10.1128/JVI.03691-14
BenteDAPathogenesis and immune response of Crimean-Congo hemorrhagic fever virus in a STAT-1 knockout mouse modelJ. Virol.201084110891001:CAS:528:DC%2BC3cXhsVeisLfI10.1128/JVI.01383-10
SpenglerJessica RKelly KeatingMMcElroyAnita KZivcecMarkoColeman-McCrayJoAnn DHarmonJessica RBollwegBrigid CGoldsmithCynthia SBergeronÉricKeckJames GZakiSherif RNicholStuart TSpiropoulouChristina FCrimean-Congo Hemorrhagic Fever in Humanized Mice Reveals Glial Cells as Primary Targets of Neurological InfectionThe Journal of Infectious Diseases201721611138613971:CAS:528:DC%2BC1cXisV2qs7fL10.1093/infdis/jix215
BergeronEVincentMJNicholSTCrimean-Congo hemorrhagic fever virus glycoprotein processing by the endoprotease SKI-1/S1P is critical for virus infectivityJ. Virol.2007811327161:CAS:528:DC%2BD2sXhtl2jtbnI10.1128/JVI.01647-07
MarziAStat1-Deficient Mice Are Not an Appropriate Model for Efficacy Testing of Recombinant Vesicular Stomatitis Virus–Based Filovirus VaccinesJ. Infect. Dis.2015212S404S4091:CAS:528:DC%2BC1cXht12lt74%3D10.1093/infdis/jiv188
XiaoXFengYZhuZDimitrovDSIdentification of a putative Crimean-Congo hemorrhagic fever virus entry factorBiochem. Biophys. Res. Commun.20114112532581:CAS:528:DC%2BC3MXps1aku7s%3D10.1016/j.bbrc.2011.06.109
WhittMAGeneration of VSV pseudotypes using recombinant ΔG-VSV for studies on virus entry, identification of entry inhibitors, and immune responses to vaccinesJ. Virol. Methods20101693653741:CAS:528:DC%2BC3cXht1WisrjM10.1016/j.jviromet.2010.08.006
GoedhalsDPaweskaJTBURTFJIdentification of human linear B-cell epitope sites on the envelope glycoproteins of Crimean-Congo haemorrhagic fever virusEpidemiol. Infect.2015143145114561:CAS:528:DC%2BC2MXlvVartrc%3D10.1017/S0950268814002271
LawsonNDStillmanEAWhittMARoseJKRecombinant vesicular stomatitis viruses fromDNA. Proc. Natl. Acad. Sci.199592447744811995PNAS...92.4477L1:CAS:528:DyaK2MXls1aks7c%3D10.1073/pnas.92.10.4477
HalperinSASix-Month Safety Data of Recombinant Vesicular Stomatitis Virus–Zaire Ebola Virus Envelope Glycoprotein Vaccine in a Phase 3 Double-Blind, Placebo-Controlled Randomized Study in Healthy AdultsJ. Infect. Dis.2017215178917981:CAS:528:DC%2BC1cXitFCrtLrK10.1093/infdis/jix189
BrownKSSafronetzDMarziAEbiharaHFeldmannHVesicular Stomatitis Virus-Based Vaccine Protects Hamsters against Lethal Challenge with Andes VirusJ. Virol.20118512781127911:CAS:5
AA Ahmed (44210_CR13) 2005; 86
44210_CR25
S Devignot (44210_CR11) 2015; 89
KS Brown (44210_CR28) 2011; 85
DA Bente (44210_CR3) 2013; 100
ND Lawson (44210_CR39) 1995; 92
AJ Sanchez (44210_CR7) 2002; 76
HR Jayakar (44210_CR46) 2002; 76
Ö Ergönül (44210_CR4) 2006; 6
A Marzi (44210_CR56) 2015; 212
MA Whitt (44210_CR40) 2010; 169
44210_CR35
DA Bente (44210_CR19) 2010; 84
O Ergonul (44210_CR5) 2012; 2
CE Mire (44210_CR29) 2013; 10
BG Coller (44210_CR38) 2017; 35
N Canakoglu (44210_CR21) 2015; 9
E Haddock (44210_CR59) 2018; 3
J Kortekaas (44210_CR24) 2015; 15
Marko Zivcec (44210_CR15) 2017; 146
A Fritzen (44210_CR53) 2018; 12
44210_CR1
CE Mire (44210_CR60) 2015; 520
A Gargili (44210_CR2) 2017; 144
K Spik (44210_CR58) 2006; 24
Jessica R Spengler (44210_CR41) 2017; 216
AM Henao-Restrepo (44210_CR36) 2017; 389
Y Suda (44210_CR42) 2016; 161
OT Preble (44210_CR55) 1980; 29
BD Lichty (44210_CR31) 2004; 10
CE Mire (44210_CR32) 2014; 9
SA Halperin (44210_CR34) 2017; 215
R Surtees (44210_CR57) 2016; 90
Chad E. Mire (44210_CR30) 2013; 7
D Goedhals (44210_CR52) 2015; 143
AJ Sanchez (44210_CR8) 2006; 80
SD Dowall (44210_CR16) 2017; 35
SM Ghiasi (44210_CR22) 2011; 18
JE Bergmann (44210_CR45) 1981; 78
LA Altamura (44210_CR9) 2007; 81
TW Geisbert (44210_CR33) 2008; 4
M Simon (44210_CR44) 2009; 385
S Bereczky (44210_CR17) 2010; 91
X Xiao (44210_CR50) 2011; 411
E Bergeron (44210_CR10) 2007; 81
X Shi (44210_CR48) 2007; 81
S Dowall (44210_CR26) 2016; 12
CE Garry (44210_CR51) 2004; 1
S Fukushi (44210_CR49) 2005; 86
JM Forger (44210_CR54) 1991; 65
A Bertolotti-ciarlet (44210_CR14) 2005; 79
M Zivcec (44210_CR18) 2013; 207
M Garbutt (44210_CR27) 2004; 78
KR Buttigieg (44210_CR23) 2014; 9
AK Overby (44210_CR47) 2007; 81
BR Erickson (44210_CR12) 2007; 361
AR Garrison (44210_CR20) 2017; 11
A Huttner (44210_CR37) 2015; 15
44210_CR43
O Ergonul (44210_CR6) 2008; 78
References_xml – reference: ZivcecMLethal Crimean-Congo hemorrhagic fever virus infection in interferon α/β receptor knockout mice is associated with high viral loads, proinflammatory responses, and coagulopathyJ. Infect. Dis.2013207190919211:CAS:528:DC%2BC3sXotlOgtbY%3D10.1093/infdis/jit061
– reference: GarryCEGarryRFProteomics computational analyses suggest that the carboxyl terminal glycoproteins of Bunyaviruses are class II viral fusion protein (beta-penetrenes)Theor. Biol. Med. Model.2004110.1186/1742-4682-1-10
– reference: SurteesRHeat Shock Protein 70 Family Members Interact with Crimean-Congo Hemorrhagic Fever Virus and Hazara Virus Nucleocapsid Proteins and Perform a Functional Role in the Nairovirus Replication CycleJ. Virol.2016909305161:CAS:528:DC%2BC2sXhs1ehsrY%3D10.1128/JVI.00661-16
– reference: GarbuttMProperties of Replication-Competent Vesicular Stomatitis Virus Vectors Expressing Glycoproteins of Filoviruses and Arenaviruses Properties of Replication-Competent Vesicular Stomatitis Virus Vectors Expressing Glycoproteins of Filoviruses and ArenavirusesJ. Virol.200478545854651:CAS:528:DC%2BD2cXjvFeqtrY%3D10.1128/JVI.78.10.5458-5465.2004
– reference: ErgonulOTreatment of Crimean-Congo hemorrhagic feverAntiviral Res.2008781251311:CAS:528:DC%2BD1cXjtleqtLY%3D10.1016/j.antiviral.2007.11.002
– reference: AltamuraLAIdentification of a novel C-terminal cleavage of Crimean-Congo hemorrhagic fever virus PreGN that leads to generation of an NSM proteinJ. Virol.2007816632421:CAS:528:DC%2BD2sXmt1Ortrs%3D10.1128/JVI.02730-06
– reference: ForgerJMBronsonRTHuangASReissCSMurine infection by vesicular stomatitis virus: initial characterization of the H-2d systemJ. Virol.199165495081:CAS:528:DyaK3MXmtVGku7s%3D1651414248957
– reference: SpikKImmunogenicity of combination DNA vaccines for Rift Valley fever virus, tick-borne encephalitis virus, Hantaan virus, and Crimean Congo hemorrhagic fever virusVaccine200624465746661:CAS:528:DC%2BD28XltF2ru7w%3D10.1016/j.vaccine.2005.08.034
– reference: GeisbertTWVesicular stomatitis virus-based Ebola vaccine is well-tolerated and protects immunocompromised nonhuman primatesPLoS Pathog.20084e100022510.1371/journal.ppat.1000225
– reference: DowallSDCarrollMWHewsonRDevelopment of vaccines against Crimean-Congo haemorrhagic fever virusVaccine201735601560231:CAS:528:DC%2BC2sXhtFamtr%2FK10.1016/j.vaccine.2017.05.031
– reference: MireChad E.GeisbertJoan B.MarziAndreaAgansKrystle N.FeldmannHeinzGeisbertThomas W.Vesicular Stomatitis Virus-Based Vaccines Protect Nonhuman Primates against Bundibugyo ebolavirusPLoS Neglected Tropical Diseases2013712e260010.1371/journal.pntd.0002600
– reference: FritzenAEpitope-mapping of the glycoprotein from Crimean-Congo hemorrhagic fever virus using a microarray approachPLoS Negl. Trop. Dis.201812e000659810.1371/journal.pntd.0006598
– reference: Henao-RestrepoAMEfficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola Ça Suffi t!)Lancet20173895055181:CAS:528:DC%2BC28XitFGitbbJ10.1016/S0140-6736(16)32621-6
– reference: HuttnerAThe effect of dose on the safety and immunogenicity of the VSV Ebola candidate vaccine: A randomised double-blind, placebo-controlled phase 1/2 trialLancet Infect. Dis.201515115611661:CAS:528:DC%2BC2MXht1yjsLfM10.1016/S1473-3099(15)00154-1
– reference: BergeronEVincentMJNicholSTCrimean-Congo hemorrhagic fever virus glycoprotein processing by the endoprotease SKI-1/S1P is critical for virus infectivityJ. Virol.2007811327161:CAS:528:DC%2BD2sXhtl2jtbnI10.1128/JVI.01647-07
– reference: Adams, M. J. et al. Changes to taxonomy and the International Code of Virus Classification and Nomenclature ratified by the International Committee on Taxonomy of Viruses (2017). Arch. Virol. 162 (2017).
– reference: DowallSA Crimean-Congo hemorrhagic fever (CCHF) viral vaccine expressing nucleoprotein is immunogenic but fails to confer protection against lethal diseaseHum. Vaccin. Immunother.2016125195271:STN:280:DC%2BC287mt1Gjuw%3D%3D10.1080/21645515.2015.1078045
– reference: BereczkySCrimean-Congo hemorrhagic fever virus infection is lethal for adult type I interferon receptor-knockout miceJ. Gen. Virol.201091147314771:CAS:528:DC%2BC3cXnsFKhtbo%3D10.1099/vir.0.019034-0
– reference: GhiasiSMSalmanianAHChinikarSZakeriSMice orally immunized with a transgenic plant expressing the glycoprotein of Crimean-Congo hemorrhagic fever virusClin. Vaccine Immunol.201118203120371:CAS:528:DC%2BC3MXhs1yksrnK10.1128/CVI.05352-11
– reference: Hinkula, J. et al. Immunization with DNA Plasmids Coding for Crimean-Congo Hemorrhagic Fever Virus Capsid and Envelope Proteins and/or Virus-Like Particles Induces Protection and Survival in Challenged Mice. J. Virol. 91 (2017).
– reference: XiaoXFengYZhuZDimitrovDSIdentification of a putative Crimean-Congo hemorrhagic fever virus entry factorBiochem. Biophys. Res. Commun.20114112532581:CAS:528:DC%2BC3MXps1aku7s%3D10.1016/j.bbrc.2011.06.109
– reference: GargiliAThe role of ticks in the maintenance and transmission of Crimean-Congo hemorrhagic fever virus: A review of published field and laboratory studiesAntiviral Res.2017144931191:CAS:528:DC%2BC2sXpslSqtLs%3D10.1016/j.antiviral.2017.05.010
– reference: MireCESingle injection recombinant vesicular stomatitis virus vaccines protect ferrets against lethal Nipah virus diseaseVirol. J.20131035310.1186/1743-422X-10-353
– reference: ShiXKohlALiPElliottRMRole of the cytoplasmic tail domains of Bunyamwera orthobunyavirus glycoproteins Gn and Gc in virus assembly and morphogenesisJ. Virol.20078110151601:CAS:528:DC%2BD2sXhtVehtL%2FP10.1128/JVI.00573-07
– reference: SpenglerJessica RKelly KeatingMMcElroyAnita KZivcecMarkoColeman-McCrayJoAnn DHarmonJessica RBollwegBrigid CGoldsmithCynthia SBergeronÉricKeckJames GZakiSherif RNicholStuart TSpiropoulouChristina FCrimean-Congo Hemorrhagic Fever in Humanized Mice Reveals Glial Cells as Primary Targets of Neurological InfectionThe Journal of Infectious Diseases201721611138613971:CAS:528:DC%2BC1cXisV2qs7fL10.1093/infdis/jix215
– reference: SudaYAnalysis of the entry mechanism of Crimean-Congo hemorrhagic fever virus, using a vesicular stomatitis virus pseudotyping systemArch. Virol.2016161144714541:CAS:528:DC%2BC28XjsFequr4%3D10.1007/s00705-016-2803-1
– reference: DevignotSBergeronENicholSMirazimiAWeberFA virus-like particle system identifies the endonuclease domain of Crimean-Congo hemorrhagic fever virusJ. Virol.2015895957671:CAS:528:DC%2BC2MXosFSjtL8%3D10.1128/JVI.03691-14
– reference: ButtigiegKRA novel vaccine against Crimean-Congo haemorrhagic fever protects 100% of animals against lethal challenge in a mouse modelPLoS One20149e915162014PLoSO...991516B10.1371/journal.pone.0091516
– reference: AhmedAAPresence of broadly reactive and group-specific neutralizing epitopes on newly described isolates of Crimean-Congo hemorrhagic fever virusJ. Gen. Virol.200586332733361:CAS:528:DC%2BD2MXht12ntL%2FP10.1099/vir.0.81175-0
– reference: HaddockEA cynomolgus macaque model for Crimean–Congo haemorrhagic feverNat. Microbiol.201835565621:CAS:528:DC%2BC1cXnsVGrtro%3D10.1038/s41564-018-0141-7
– reference: HalperinSASix-Month Safety Data of Recombinant Vesicular Stomatitis Virus–Zaire Ebola Virus Envelope Glycoprotein Vaccine in a Phase 3 Double-Blind, Placebo-Controlled Randomized Study in Healthy AdultsJ. Infect. Dis.2017215178917981:CAS:528:DC%2BC1cXitFCrtLrK10.1093/infdis/jix189
– reference: CollerBGClinical development of a recombinant Ebola vaccine in the midst of an unprecedented epidemicVaccine2017354465446910.1016/j.vaccine.2017.05.097
– reference: BenteDAPathogenesis and immune response of Crimean-Congo hemorrhagic fever virus in a STAT-1 knockout mouse modelJ. Virol.201084110891001:CAS:528:DC%2BC3cXhsVeisLfI10.1128/JVI.01383-10
– reference: WhittMAGeneration of VSV pseudotypes using recombinant ΔG-VSV for studies on virus entry, identification of entry inhibitors, and immune responses to vaccinesJ. Virol. Methods20101693653741:CAS:528:DC%2BC3cXht1WisrjM10.1016/j.jviromet.2010.08.006
– reference: MireCESingle-dose attenuated Vesiculovax vaccines protect primates against Ebola Makona virusNature20155206886912015Natur.520..688M1:CAS:528:DC%2BC2MXnsVWqtL4%3D10.1038/nature14428
– reference: GoedhalsDPaweskaJTBURTFJIdentification of human linear B-cell epitope sites on the envelope glycoproteins of Crimean-Congo haemorrhagic fever virusEpidemiol. Infect.2015143145114561:CAS:528:DC%2BC2MXlvVartrc%3D10.1017/S0950268814002271
– reference: BenteDACrimean-Congo hemorrhagic fever: History, epidemiology, pathogenesis, clinical syndrome and genetic diversityAntiviral Res.20131001591891:CAS:528:DC%2BC3sXhvVWksLzI10.1016/j.antiviral.2013.07.006
– reference: SanchezAJVincentMJNicholSTCharacterization of the glycoproteins of Crimean-Congo hemorrhagic fever virusJ. Virol.2002767263751:CAS:528:DC%2BD38XltVylsL8%3D10.1128/JVI.76.14.7263-7275.2002
– reference: MireCEDurability of a vesicular stomatitis virus-based marburg virus vaccine in nonhuman primatesPLoS One201491710.1371/journal.pone.0094355
– reference: CanakogluNImmunization of Knock-Out α/β Interferon Receptor Mice against High Lethal Dose of Crimean-Congo Hemorrhagic Fever Virus with a Cell Culture Based VaccinePLoS Negl. Trop. Dis.2015911410.1371/journal.pntd.0003579
– reference: MarziAStat1-Deficient Mice Are Not an Appropriate Model for Efficacy Testing of Recombinant Vesicular Stomatitis Virus–Based Filovirus VaccinesJ. Infect. Dis.2015212S404S4091:CAS:528:DC%2BC1cXht12lt74%3D10.1093/infdis/jiv188
– reference: LawsonNDStillmanEAWhittMARoseJKRecombinant vesicular stomatitis viruses fromDNA. Proc. Natl. Acad. Sci.199592447744811995PNAS...92.4477L1:CAS:528:DyaK2MXls1aks7c%3D10.1073/pnas.92.10.4477
– reference: BrownKSSafronetzDMarziAEbiharaHFeldmannHVesicular Stomatitis Virus-Based Vaccine Protects Hamsters against Lethal Challenge with Andes VirusJ. Virol.20118512781127911:CAS:528:DC%2BC3MXhsFaks7fL10.1128/JVI.00794-11
– reference: KortekaasJCrimean-Congo Hemorrhagic Fever Virus Subunit Vaccines Induce High Levels of Neutralizing Antibodies But No Protection in STAT1 Knockout MiceVector-Borne Zoonotic Dis.20151575976410.1089/vbz.2015.1855
– reference: ErgönülÖCrimean-Congo haemorrhagic feverLancet Infect. Dis.2006620321410.1016/S1473-3099(06)70435-2
– reference: EricksonBRDeydeVSanchezAJVincentMJNicholSTN-linked glycosylation of Gn (but not Gc) is important for Crimean Congo hemorrhagic fever virus glycoprotein localization and transportVirology20073613483551:CAS:528:DC%2BD2sXksV2gtLY%3D10.1016/j.virol.2006.11.023
– reference: SimonMJohanssonCLundkvistÅMirazimiAMicrotubule-dependent and microtubule-independent steps in Crimean-Congo hemorrhagic fever virus replication cycleVirology20093853133221:CAS:528:DC%2BD1MXisFOnsbY%3D10.1016/j.virol.2008.11.020
– reference: PrebleOTCostelloLEHuangDDBarmadaMANeurovirulence mutant of vesicular stomatitis virus with an altered target cell tropism in vivoInfect. Immun.198029744571:CAS:528:DyaL3cXlt12qurs%3D6163714551188
– reference: JayakarHRWhittMAIdentification of Two Additional Translation Products from the Matrix (M) Gene That Contribute to Vesicular Stomatitis Virus CytopathologyJ. Virol.200276801180181:CAS:528:DC%2BD38XlslOksrg%3D10.1128/JVI.76.16.8011-8018.2002
– reference: ZivcecMarkoGuerreroLisa I.W.AlbariñoCésar G.BergeronÉricNicholStuart T.SpiropoulouChristina F.Identification of broadly neutralizing monoclonal antibodies against Crimean-Congo hemorrhagic fever virusAntiviral Research20171461121201:CAS:528:DC%2BC2sXhsVWmt7rK10.1016/j.antiviral.2017.08.014
– reference: BergmannJETokuyasuKTSingerSJPassage of an integral membrane protein, the vesicular stomatitis virus glycoprotein, through the Golgi apparatus en route to the plasma membraneProc. from Natl. Acad. Sci.198178174617501981PNAS...78.1746B1:CAS:528:DyaL3MXhs12ls7k%3D10.1073/pnas.78.3.1746
– reference: FukushiSVesicular stomatitis virus pseudotyped with severe acute respiratory syndrome coronavirus spike proteinJ. Gen. Virol.200586226922741:CAS:528:DC%2BD2MXpvVCgtL0%3D10.1099/vir.0.80955-0
– reference: Bertolotti-ciarletACellular Localization and Antigenic Characterization of Crimean-Congo Hemorrhagic Fever Virus GlycoproteinsSociety200579615261611:CAS:528:DC%2BD2MXkt1WitLY%3D
– reference: OverbyAKPopovVLPetterssonRFNeveEPAThe cytoplasmic tails of Uukuniemi Virus (Bunyaviridae) G(N) and G(C) glycoproteins are important for intracellular targeting and the budding of virus-like particlesJ. Virol.200781113819110.1128/JVI.00767-07
– reference: SanchezAJVincentMJEricksonBRNicholSTCrimean-congo hemorrhagic fever virus glycoprotein precursor is cleaved by Furin-like and SKI-1 proteases to generate a novel 38-kilodalton glycoproteinJ. Virol.200680514251:CAS:528:DC%2BD28Xjslalurg%3D10.1128/JVI.80.1.514-525.2006
– reference: LichtyBDPowerATStojdlDFBellJCVesicular stomatitis virus: Re-inventing the bulletTrends Mol. Med.2004102102161:CAS:528:DC%2BD2cXjs1Wgtbk%3D10.1016/j.molmed.2004.03.003
– reference: ErgonulOCrimean-Congo hemorrhagic fever virus: New outbreaks, new discoveriesCurr. Opin. Virol.2012221522010.1016/j.coviro.2012.03.001
– reference: Fuchs, J. D. et al. First-in-Human Evaluation of the Safety and Immunogenicity of a Recombinant Vesicular Stomatitis Virus Human Immunodeficiency Virus-1 Vaccine (HVTN 090). Open Forum Infect. Dis. 2 (2015).
– reference: GarrisonARA DNA vaccine for Crimean-Congo hemorrhagic fever protects against disease and death in two lethal mouse modelsPLoS Negl. Trop. Dis.201711E000590810.1371/journal.pntd.0005908
– reference: Shtanko, O., Nikitina, R. A., Altuntas, C. Z., Chepurnov, A. A. & Davey, R. A. Crimean-Congo Hemorrhagic Fever Virus Entry into Host Cells Occurs through the Multivesicular Body and Requires ESCRT Regulators. PLoS Pathog. 10 (2014).
– volume: 12
  start-page: e0006598
  year: 2018
  ident: 44210_CR53
  publication-title: PLoS Negl. Trop. Dis.
  doi: 10.1371/journal.pntd.0006598
– volume: 76
  start-page: 7263
  year: 2002
  ident: 44210_CR7
  publication-title: J. Virol.
  doi: 10.1128/JVI.76.14.7263-7275.2002
– volume: 10
  start-page: 353
  year: 2013
  ident: 44210_CR29
  publication-title: Virol. J.
  doi: 10.1186/1743-422X-10-353
– volume: 79
  start-page: 6152
  year: 2005
  ident: 44210_CR14
  publication-title: Society
– volume: 6
  start-page: 203
  year: 2006
  ident: 44210_CR4
  publication-title: Lancet Infect. Dis.
  doi: 10.1016/S1473-3099(06)70435-2
– volume: 24
  start-page: 4657
  year: 2006
  ident: 44210_CR58
  publication-title: Vaccine
  doi: 10.1016/j.vaccine.2005.08.034
– volume: 169
  start-page: 365
  year: 2010
  ident: 44210_CR40
  publication-title: J. Virol. Methods
  doi: 10.1016/j.jviromet.2010.08.006
– volume: 361
  start-page: 348
  year: 2007
  ident: 44210_CR12
  publication-title: Virology
  doi: 10.1016/j.virol.2006.11.023
– volume: 80
  start-page: 514
  year: 2006
  ident: 44210_CR8
  publication-title: J. Virol.
  doi: 10.1128/JVI.80.1.514-525.2006
– ident: 44210_CR35
  doi: 10.1093/ofid/ofv082
– volume: 89
  start-page: 5957
  year: 2015
  ident: 44210_CR11
  publication-title: J. Virol.
  doi: 10.1128/JVI.03691-14
– volume: 9
  start-page: 1
  year: 2015
  ident: 44210_CR21
  publication-title: PLoS Negl. Trop. Dis.
  doi: 10.1371/journal.pntd.0003579
– volume: 15
  start-page: 1156
  year: 2015
  ident: 44210_CR37
  publication-title: Lancet Infect. Dis.
  doi: 10.1016/S1473-3099(15)00154-1
– volume: 92
  start-page: 4477
  year: 1995
  ident: 44210_CR39
  publication-title: DNA. Proc. Natl. Acad. Sci.
  doi: 10.1073/pnas.92.10.4477
– volume: 385
  start-page: 313
  year: 2009
  ident: 44210_CR44
  publication-title: Virology
  doi: 10.1016/j.virol.2008.11.020
– volume: 411
  start-page: 253
  year: 2011
  ident: 44210_CR50
  publication-title: Biochem. Biophys. Res. Commun.
  doi: 10.1016/j.bbrc.2011.06.109
– volume: 84
  start-page: 11089
  year: 2010
  ident: 44210_CR19
  publication-title: J. Virol.
  doi: 10.1128/JVI.01383-10
– volume: 9
  start-page: e91516
  year: 2014
  ident: 44210_CR23
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0091516
– volume: 86
  start-page: 3327
  year: 2005
  ident: 44210_CR13
  publication-title: J. Gen. Virol.
  doi: 10.1099/vir.0.81175-0
– volume: 9
  start-page: 1
  year: 2014
  ident: 44210_CR32
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0094355
– volume: 81
  start-page: 11381
  year: 2007
  ident: 44210_CR47
  publication-title: J. Virol.
  doi: 10.1128/JVI.00767-07
– volume: 1
  year: 2004
  ident: 44210_CR51
  publication-title: Theor. Biol. Med. Model.
  doi: 10.1186/1742-4682-1-10
– volume: 81
  start-page: 13271
  year: 2007
  ident: 44210_CR10
  publication-title: J. Virol.
  doi: 10.1128/JVI.01647-07
– volume: 2
  start-page: 215
  year: 2012
  ident: 44210_CR5
  publication-title: Curr. Opin. Virol.
  doi: 10.1016/j.coviro.2012.03.001
– volume: 144
  start-page: 93
  year: 2017
  ident: 44210_CR2
  publication-title: Antiviral Res.
  doi: 10.1016/j.antiviral.2017.05.010
– volume: 86
  start-page: 2269
  year: 2005
  ident: 44210_CR49
  publication-title: J. Gen. Virol.
  doi: 10.1099/vir.0.80955-0
– volume: 90
  start-page: 9305
  year: 2016
  ident: 44210_CR57
  publication-title: J. Virol.
  doi: 10.1128/JVI.00661-16
– volume: 78
  start-page: 5458
  year: 2004
  ident: 44210_CR27
  publication-title: J. Virol.
  doi: 10.1128/JVI.78.10.5458-5465.2004
– volume: 85
  start-page: 12781
  year: 2011
  ident: 44210_CR28
  publication-title: J. Virol.
  doi: 10.1128/JVI.00794-11
– volume: 215
  start-page: 1789
  year: 2017
  ident: 44210_CR34
  publication-title: J. Infect. Dis.
  doi: 10.1093/infdis/jix189
– volume: 146
  start-page: 112
  year: 2017
  ident: 44210_CR15
  publication-title: Antiviral Research
  doi: 10.1016/j.antiviral.2017.08.014
– volume: 7
  start-page: e2600
  issue: 12
  year: 2013
  ident: 44210_CR30
  publication-title: PLoS Neglected Tropical Diseases
  doi: 10.1371/journal.pntd.0002600
– volume: 76
  start-page: 8011
  year: 2002
  ident: 44210_CR46
  publication-title: J. Virol.
  doi: 10.1128/JVI.76.16.8011-8018.2002
– volume: 520
  start-page: 688
  year: 2015
  ident: 44210_CR60
  publication-title: Nature
  doi: 10.1038/nature14428
– ident: 44210_CR43
  doi: 10.1371/journal.ppat.1004390
– volume: 3
  start-page: 556
  year: 2018
  ident: 44210_CR59
  publication-title: Nat. Microbiol.
  doi: 10.1038/s41564-018-0141-7
– volume: 91
  start-page: 1473
  year: 2010
  ident: 44210_CR17
  publication-title: J. Gen. Virol.
  doi: 10.1099/vir.0.019034-0
– ident: 44210_CR1
  doi: 10.1007/s00705-017-3358-5
– ident: 44210_CR25
  doi: 10.1128/JVI.02076-16
– volume: 100
  start-page: 159
  year: 2013
  ident: 44210_CR3
  publication-title: Antiviral Res.
  doi: 10.1016/j.antiviral.2013.07.006
– volume: 212
  start-page: S404
  year: 2015
  ident: 44210_CR56
  publication-title: J. Infect. Dis.
  doi: 10.1093/infdis/jiv188
– volume: 35
  start-page: 4465
  year: 2017
  ident: 44210_CR38
  publication-title: Vaccine
  doi: 10.1016/j.vaccine.2017.05.097
– volume: 10
  start-page: 210
  year: 2004
  ident: 44210_CR31
  publication-title: Trends Mol. Med.
  doi: 10.1016/j.molmed.2004.03.003
– volume: 35
  start-page: 6015
  year: 2017
  ident: 44210_CR16
  publication-title: Vaccine
  doi: 10.1016/j.vaccine.2017.05.031
– volume: 4
  start-page: e1000225
  year: 2008
  ident: 44210_CR33
  publication-title: PLoS Pathog.
  doi: 10.1371/journal.ppat.1000225
– volume: 216
  start-page: 1386
  issue: 11
  year: 2017
  ident: 44210_CR41
  publication-title: The Journal of Infectious Diseases
  doi: 10.1093/infdis/jix215
– volume: 29
  start-page: 744
  year: 1980
  ident: 44210_CR55
  publication-title: Infect. Immun.
  doi: 10.1128/iai.29.2.744-757.1980
– volume: 81
  start-page: 6632
  year: 2007
  ident: 44210_CR9
  publication-title: J. Virol.
  doi: 10.1128/JVI.02730-06
– volume: 143
  start-page: 1451
  year: 2015
  ident: 44210_CR52
  publication-title: Epidemiol. Infect.
  doi: 10.1017/S0950268814002271
– volume: 65
  start-page: 4950
  year: 1991
  ident: 44210_CR54
  publication-title: J. Virol.
  doi: 10.1128/jvi.65.9.4950-4958.1991
– volume: 81
  start-page: 10151
  year: 2007
  ident: 44210_CR48
  publication-title: J. Virol.
  doi: 10.1128/JVI.00573-07
– volume: 207
  start-page: 1909
  year: 2013
  ident: 44210_CR18
  publication-title: J. Infect. Dis.
  doi: 10.1093/infdis/jit061
– volume: 11
  start-page: E0005908
  year: 2017
  ident: 44210_CR20
  publication-title: PLoS Negl. Trop. Dis.
  doi: 10.1371/journal.pntd.0005908
– volume: 78
  start-page: 125
  year: 2008
  ident: 44210_CR6
  publication-title: Antiviral Res.
  doi: 10.1016/j.antiviral.2007.11.002
– volume: 161
  start-page: 1447
  year: 2016
  ident: 44210_CR42
  publication-title: Arch. Virol.
  doi: 10.1007/s00705-016-2803-1
– volume: 18
  start-page: 2031
  year: 2011
  ident: 44210_CR22
  publication-title: Clin. Vaccine Immunol.
  doi: 10.1128/CVI.05352-11
– volume: 12
  start-page: 519
  year: 2016
  ident: 44210_CR26
  publication-title: Hum. Vaccin. Immunother.
  doi: 10.1080/21645515.2015.1078045
– volume: 15
  start-page: 759
  year: 2015
  ident: 44210_CR24
  publication-title: Vector-Borne Zoonotic Dis.
  doi: 10.1089/vbz.2015.1855
– volume: 78
  start-page: 1746
  year: 1981
  ident: 44210_CR45
  publication-title: Proc. from Natl. Acad. Sci.
  doi: 10.1073/pnas.78.3.1746
– volume: 389
  start-page: 505
  year: 2017
  ident: 44210_CR36
  publication-title: Lancet
  doi: 10.1016/S0140-6736(16)32621-6
SSID ssj0000529419
Score 2.4881995
Snippet Crimean-Congo hemorrhagic fever virus (CCHFV), a tick-borne bunyavirus, can cause a life-threatening hemorrhagic syndrome in humans but not in its animal host....
Abstract Crimean-Congo hemorrhagic fever virus (CCHFV), a tick-borne bunyavirus, can cause a life-threatening hemorrhagic syndrome in humans but not in its...
SourceID doaj
pubmedcentral
proquest
pubmed
crossref
springer
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 7755
SubjectTerms 13
631/326/590
631/326/596
64
Animal models
Animals
Antibodies, Neutralizing - immunology
Antibodies, Viral - immunology
Cell Line
Crimean hemorrhagic fever
Disease Models, Animal
Epidemics
Expression vectors
Female
Glycoproteins
Glycoproteins - immunology
Hemorrhage
Hemorrhagic Fever Virus, Crimean-Congo - immunology
Hemorrhagic Fever Virus, Crimean-Congo - pathogenicity
Hemorrhagic Fever, Crimean - immunology
Hemorrhagic Fever, Crimean - prevention & control
Humanities and Social Sciences
Immunoglobulin G
Mice
Mice, Knockout
multidisciplinary
Replication
Science
Science (multidisciplinary)
Stat1 protein
STAT1 Transcription Factor - genetics
Stomatitis
Vaccination - methods
Vaccines
Vaccines - immunology
Vesicular stomatitis Indiana virus - immunology
Vesicular stomatitis Indiana virus - pathogenicity
Vesiculovirus - immunology
Viruses
SummonAdditionalLinks – databaseName: Biological Science Database
  dbid: M7P
  link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9QwELaggMSFNzRQkJG4gdXEduz4hGjFqheqlYBVT1h-ZRsJJW2yi8S_Z-xkt1oevXCNHcn2vD3j-RB6EwpKawjSSB4EBChBUGJlXQIvc1Vzz5koTAKbkKen1dmZmk8XbsNUVrnRiUlR-87FO_LDiDtNBRjD4v3FJYmoUTG7OkFo3ES3YpcElkr35ts7lpjF4oWa3srkrDocwF7FN2WFIpxDtEPEjj1Kbfv_5mv-WTL5W940maPZ_f_dyAN0b3JE8YeRcx6iG6F9hO6M0JQ_H6NvizA0qUYVf151ya1tBrxo-vVAjsDyebwwLibl8Xzs9DDgT6BzsFmaBjxOHOHCgmnJcdcuO3wS63n7cwNqFs8CSM8T9HX28cvxCZmwGIiDEGdFuFHBWia9k8bm3uXMi1CEwgVZelVJaqzirnZSWiVsZYKtRQwWhRRGFLZkT9Fe27VhH-FacJm73NtcuPhOVgXOTa1qOBclPPUZKjYU0W5qVB7xMr7rlDBnlR6pqIGKOlFRiwy93f5zMbbpuHb2UST0dmZssZ0-dP1STxKrOa0lddwrGRxXuam8UtZTDsaNB1_VGTrY0FdPcj_oK-Jm6PV2GCQ2pmFMG7p1nMNiG72S0ww9G7lquxIG7i8DjztDcoffdpa6O9I256kruADHnUqVoXcbzrxa1r-P4vn1u3iB7tIoLHlJKDtAe6t-HV6i2-4H8Fz_KknbL2loMcw
  priority: 102
  providerName: ProQuest
Title Vesicular Stomatitis Virus-Based Vaccine Protects Mice against Crimean-Congo Hemorrhagic Fever
URI https://link.springer.com/article/10.1038/s41598-019-44210-6
https://www.ncbi.nlm.nih.gov/pubmed/31123310
https://www.proquest.com/docview/2229262831
https://www.proquest.com/docview/2232134542
https://pubmed.ncbi.nlm.nih.gov/PMC6533279
https://doaj.org/article/42f72c4d97ec490a8d99bd24eb14ed8f
Volume 9
WOSCitedRecordID wos000468770600020&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVAON
  databaseName: DOAJ
  customDbUrl:
  eissn: 2045-2322
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0000529419
  issn: 2045-2322
  databaseCode: DOA
  dateStart: 20110101
  isFulltext: true
  titleUrlDefault: https://www.doaj.org/
  providerName: Directory of Open Access Journals
– providerCode: PRVHPJ
  databaseName: ROAD: Directory of Open Access Scholarly Resources
  customDbUrl:
  eissn: 2045-2322
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0000529419
  issn: 2045-2322
  databaseCode: M~E
  dateStart: 20110101
  isFulltext: true
  titleUrlDefault: https://road.issn.org
  providerName: ISSN International Centre
– providerCode: PRVPQU
  databaseName: Biological Science Database
  customDbUrl:
  eissn: 2045-2322
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0000529419
  issn: 2045-2322
  databaseCode: M7P
  dateStart: 20110101
  isFulltext: true
  titleUrlDefault: http://search.proquest.com/biologicalscijournals
  providerName: ProQuest
– providerCode: PRVPQU
  databaseName: Health & Medical Collection
  customDbUrl:
  eissn: 2045-2322
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0000529419
  issn: 2045-2322
  databaseCode: 7X7
  dateStart: 20110101
  isFulltext: true
  titleUrlDefault: https://search.proquest.com/healthcomplete
  providerName: ProQuest
– providerCode: PRVPQU
  databaseName: ProQuest Central
  customDbUrl:
  eissn: 2045-2322
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0000529419
  issn: 2045-2322
  databaseCode: BENPR
  dateStart: 20110101
  isFulltext: true
  titleUrlDefault: https://www.proquest.com/central
  providerName: ProQuest
– providerCode: PRVPQU
  databaseName: Publicly Available Content Database
  customDbUrl:
  eissn: 2045-2322
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0000529419
  issn: 2045-2322
  databaseCode: PIMPY
  dateStart: 20110101
  isFulltext: true
  titleUrlDefault: http://search.proquest.com/publiccontent
  providerName: ProQuest
– providerCode: PRVPQU
  databaseName: Science Database
  customDbUrl:
  eissn: 2045-2322
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0000529419
  issn: 2045-2322
  databaseCode: M2P
  dateStart: 20110101
  isFulltext: true
  titleUrlDefault: https://search.proquest.com/sciencejournals
  providerName: ProQuest
link http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lj9MwEB7BLkhcEG8CS2UkbhBt4rh2fKSrrZZDq4hHVS5EfmU3EkpWTbsS_56xk5YtzwsXH2JHsjyfPd_I428AXrmU0gqDtDhxHAMUx2msRTVGLDNZMcsynqpQbELM5_lyKYtrpb58TlgvD9wv3DGjlaCGWSmcYTJRuZVSW8rwjGHO5pU_fZH1XAumelVvKlkqh1cySZYfd-ip_GuyVMaMYZwT8z1PFAT7f8cyf02W_OnGNDii6T24OzBI8raf-X244ZoHcLuvKfntIXxZuK4OyaXkw7oNfLTuyKJebbp4gi7LkoUy_jadFL1EQ0dmeFgQda5qpIrE1_lyqolP2ua8JWc-EXd1ofB8JFOHsH8En6anH0_O4qGIQmwwNlnHTEmndSasEUon1iSZ5S51qXFibGUuqNKSmcoIoSXXuXK64j7K44Irnupx9hgOmrZxT4FUnInEJFYn3PgHrtIxpipZUXRp3FIbQbpd0NIMCuO-0MXXMtx0Z3nZG6FEI5TBCCWP4PXun8teX-OvoyfeTruRXhs7fEDElANiyn8hJoKjrZXLYcN2pS9rTjlyrTSCl7tu3Gr-_kQ1rt34MZnXvxszGsGTHhS7mWTIWzOkyhGIPbjsTXW_p6kvgpw3R8ZNhYzgzRZYP6b156V49j-W4jncoX5HJOOYZkdwsF5t3Au4Za4QmasR3BRLEdp8BIeT03nxfhS2GbYzWvhWYHtYvJsVn78DcMwrvA
linkProvider Directory of Open Access Journals
linkToHtml http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1bb9MwFLamAYIX7rDAACPBE1hLHNeOHxBig6rTtqoSo9rTjGM7XaUpGU0L2p_iN3LsJJ3KZW974DV2JF--c7OPz4fQK5dQWkCQRmLHIUBxnJJcFD3AMpMFsyzliQ5kE2I4zI6O5GgN_ezewvi0yk4nBkVtK-PPyLc87zTlYAyT92ffiGeN8rerHYVGA4s9d_4DQrb63e5H2N_XlPY_He4MSMsqQAw463PCtHR5ngprhM5ja-LUcpe4xDjRsxCBU51LZgojRC55nmmXF9yHPVxwzZPcs0SAyr8GbgTNQqrgaHmm42_NWCLbtzlxmm3VYB_9G7ZEEsYguiJ8xf4FmoC_-bZ_pmj-dk8bzF__zv-2cHfR7dbRxh8aybiH1lx5H91oqDfPH6DjsaunIQcXf55XwW2f1ng8nS1qsg2W3eKxNj7pAI-aShY1PgCdivVET8Gjxp4OzemS7FTlpMIDn688O9FgRnDfgXZ4iL5cyeQeofWyKt0GwgVnIjaxzWNu_Dtg6RjThSxgHyS31EYo6RCgTFuI3fOBnKqQEJBmqkGNAtSogBrFI_Rm-c9ZU4bk0t7bHljLnr6EePhQzSaq1UiK0UJQw6wUzjAZ68xKmVvKwHgzZ7MiQpsdnlSr12p1AaYIvVw2g0by10y6dNXC90l9mcAeoxF63KB4OZIU3PsUIooIiRV8rwx1taWcnoSq5xwCEypkhN52knAxrH8vxZPLZ_EC3RwcHuyr_d3h3lN0i3pBjXuEpptofT5buGfouvkO-Js9D5KO0derlpBfyeSRUQ
linkToPdf http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Jb9QwFLaqsogL-xIoYCQ4gTWJ47HjA0K0ZdSqMBoJGPVU49jONBJKymQG1L_Gr-PZSaYalt564Bo7kpfvbfbz-xB67hJKCwjSSOw4BCiOU5KLYghYZrJglqU80YFsQozH2eGhnGygn_1bGJ9W2evEoKhtbfwZ-cDzTlMOxjAZFF1axGR39ObkG_EMUv6mtafTaCFy4E5_QPjWvN7fhb1-Qeno3aedPdIxDBADjvuCMC1dnqfCGqHz2Jo4tdwlLjFODC1E41TnkpnCCJFLnmfa5QX3IRAXXPMk94wRoP4vCV-0PKQNTlbnO_4GjSWye6cTp9mgAVvp37MlkjAGkRbha7YwUAb8zc_9M13ztzvbYApHN_7nRbyJrncOOH7bSswttOGq2-hKS8l5egcdTV1Thtxc_HFRB3e-bPC0nC8bsg0W3-KpNj4ZAU_aChcN_gC6FuuZLsHTxp4mzemK7NTVrMZ7Po95fqzBvOCRA61xF32-kMndQ5tVXbkHCBecidjENo-58e-DpWNMF7KAPZHcUhuhpEeDMl2Bds8T8lWFRIE0Uy2CFCBIBQQpHqGXq39O2vIk5_be9iBb9fSlxcOHej5TnaZSjBaCGmalcIbJWGdWytxSBkadOZsVEdrqsaU6fdeoM2BF6NmqGTSVv37SlauXvk_qywcOGY3Q_RbRq5Gk4PanEGlESKxhfW2o6y1VeRyqoXMIWKiQEXrVS8XZsP69FA_Pn8VTdBUEQ73fHx88Qteol9l4SGi6hTYX86V7jC6b7wC_-ZMg9Bh9uWgB-QUCdJoO
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Vesicular+Stomatitis+Virus-Based+Vaccine+Protects+Mice+against+Crimean-Congo+Hemorrhagic+Fever&rft.jtitle=Scientific+reports&rft.au=Sergio+E.+Rodriguez&rft.au=Robert+W.+Cross&rft.au=Karla+A.+Fenton&rft.au=Dennis+A.+Bente&rft.date=2019-05-23&rft.pub=Nature+Portfolio&rft.eissn=2045-2322&rft.volume=9&rft.issue=1&rft.spage=1&rft.epage=13&rft_id=info:doi/10.1038%2Fs41598-019-44210-6&rft.externalDBID=DOA&rft.externalDocID=oai_doaj_org_article_42f72c4d97ec490a8d99bd24eb14ed8f
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2045-2322&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2045-2322&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2045-2322&client=summon